NCT06783127Recruiting
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer: An Observational Study
Source: ClinicalTrials.gov · Last updated 11 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 14 Jan 2025
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Santa Chiara Hospital
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT06783127
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 1 Jan 2023 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Olaparib treatment in a clinical trial
Who the study is looking for
- BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice
Sex: Male · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sabrina Rossetti Coordinator of this site? Confirm its status | Naples | Italy | Recruiting |
| Orazio Caffo Coordinator of this site? Confirm its status | Trento | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.